RSM01, an extended half-life RSV monoclonal antibody with a high barrier to in vitro resistance

Abstract Respiratory syncytial virus (RSV) causes substantial infant morbidity and mortality, particularly in low- and middle-income countries (LMICs). RSM01 is a long-acting RSV monoclonal antibody (mAb) in development for LMICs. In vitro generation of RSM01 resistant mutants has previously been unsuccessful. We systematically assessed the in vitro resistance barrier of RSM01 and the susceptibility of a panel of global contemporary strains to RSM01. Monoclonal antibody resistant mutants (MARMs) were generated by serially passaging triple plaque-purified RSV-A2 and RSV-B1 using HEp-2 cells under pressure from RSM01, nirsevimab, or palivizumab, followed by phenotypic and genotypic characterisation. Moderate resistance was defined as > 3-fold and high resistance as > 30-fold increase in IC 50 compared with parental virus. The susceptibility of contemporary global clinical strains to RSM01 was tested in a neutralisation assay. RSV-A and B strains developed high resistance to palivizumab and nirsevimab, while RSM01 pressure induced moderate resistance. No MARMs demonstrated a fitness advantage. RSM01 neutralised global contemporary strains. In conclusion, in vitro RSM01 resistance was infrequent and moderate and RSM01 had broad activity against circulating strains. The confirmation of the high barrier to resistance of RSM01 is encouraging and provides an alternative should resistance emerge with widespread use of current licensed anti-RSV mAbs.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-11-17
DOI
https://doi.org/10.1038/s41467-026-79029-z
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

RSM01, an extended half-life RSV monoclonal antibody with a high barrier to in vitro resistance

Jason S. McLellan, Aurelio Bonavia, Emanuele Gustani‐Buss, Louis Bont et al.
3 links
Nature Communications
Respiratory viral infections research
article

RSM01, an extended half-life RSV monoclonal antibody with a high barrier to in vitro resistance

Jason S. McLellan, Aurelio Bonavia, Emanuele Gustani‐Buss, Louis Bont, Natalie I Mazur, Eveline M. Delemarre, Jonne Terstappen, Cassandra A. L. Simonich, Vicky Lynne Baillie, Mauricio T. Caballero, Anouk Versnel, Robert Jan Lebbink, Jesse D. Bloom, Marco C. Viveen, Hanneke J.A.A. Van Zoggel, Isabelle C.E. van Lotringen, Janissa J.A. van Duijn, Klasina Chappin, Joris J.T. Roggekamp, Gavin Juviler
article en

Abstract

Abstract Respiratory syncytial virus (RSV) causes substantial infant morbidity and mortality, particularly in low- and middle-income countries (LMICs). RSM01 is a long-acting RSV monoclonal antibody (mAb) in development for LMICs. In vitro generation of RSM01 resistant mutants has previously been unsuccessful. We systematically assessed the in vitro resistance barrier of RSM01 and the susceptibility of a panel of global contemporary strains to RSM01. Monoclonal antibody resistant mutants (MARMs) were generated by serially passaging triple plaque-purified RSV-A2 and RSV-B1 using HEp-2 cells under pressure from RSM01, nirsevimab, or palivizumab, followed by phenotypic and genotypic characterisation. Moderate resistance was defined as > 3-fold and high resistance as > 30-fold increase in IC 50 compared with parental virus. The susceptibility of contemporary global clinical strains to RSM01 was tested in a neutralisation assay. RSV-A and B strains developed high resistance to palivizumab and nirsevimab, while RSM01 pressure induced moderate resistance. No MARMs demonstrated a fitness advantage. RSM01 neutralised global contemporary strains. In conclusion, in vitro RSM01 resistance was infrequent and moderate and RSM01 had broad activity against circulating strains. The confirmation of the high barrier to resistance of RSM01 is encouraging and provides an alternative should resistance emerge with widespread use of current licensed anti-RSV mAbs.

Nature Communications
Howard Hughes Medical Institute (US), Consejo Nacional de Investigaciones Científicas y Técnicas (AR), University of the Witwatersrand (ZA), University of Washington (US), National University of General San Martín (AR), Rega Institute for Medical Research (BE), University Medical Center Utrecht (NL), Fred Hutch Cancer Center (US), Centro Científico Tecnológico - San Juan (AR), Universidad Nacional de San Martín (PE), Wilhelmina Children's Hospital (NL), The University of Texas at Austin (US), KU Leuven (BE)
Bill and Melinda Gates Foundation
Good health and well-being
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon